“Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 5, no. 1, p. s19, Jan. 2021, doi: 10.25251/skin.5.supp.19.